Climb BiovsEli Lilly and Company

CLYM and LLY stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,347.11

Value $1.27T

-0.30%
LLY's page

Climb Bio (CLYM) has a market value of $735M and Eli Lilly and Company (LLY) $1.27T. Over the last year, with dividends, CLYM moved +399.5% and LLY +29.1%. Dividend yield: CLYM none, LLY 0.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CLYM$735M

    LLY$1.27T

    LLY is 1,728 times CLYM

  • Revenue, 12 months

    CLYM–

    LLY$86.5B

  • Net income, 12 months

    CLYM-$59M

    LLY$27.6B

  • Operating margin

    CLYM–

    LLY–

  • ROIC

    CLYM-33.4%

    LLY35.5%

    68.9 points apart

  • P/E

    CLYM–

    LLY46.1

  • Dividend yield

    CLYM0.0%

    LLY0.5%

    0.5 points apart

  • 5-year return

    CLYM-48.5%

    LLY+439.5%

    488.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CLYM-48.5%

LLY+439.5%

020040060020222023202420252026
Returns by period
PeriodCLYMWith dividendsLLYWith dividends
1 year since November 19, 2025+399.5%Price +399.5%+29.1%Price +28.3%
3 years since November 20, 2023+261.8%+53.5% a yearPrice +261.8%+130.0%+32.0% a yearPrice +125.4%
5 years since November 19, 2021-48.5%-12.4% a yearPrice -48.5%+439.5%+40.1% a yearPrice +416.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CLYMClimb BioLLYEli Lilly and Company

Valuation

CLYMLLY
Valuation
Price$9.19$1,347.11
Market value$735M$1.27T
Enterprise value (EV)$530M$1.32T
P/E–46.1
P/E, 5-year median–49.9
P/B3.231.6
EV/EBIT–37.8
Free cash flow yield–1.6%

Results and growth

CLYMLLY
Results and growth
Revenue, 12 months–$86.5B
Net income, 12 months-$59M$27.6B
Free cash flow, 12 months-$54M$19.7B
Earnings per share, 12 months-$0.81$30.81
Revenue growth, year on year–44.7%
Revenue growth a year, past–+21.6%over 5 years
EPS growth a year, past–+27.6%over 5 years

Margins and returns on capital

CLYMLLY
Margins and returns on capital
Gross margin–83.6%
Operating margin––
Net margin–31.9%
ROIC-33.4%35.5%
ROE-31.1%88.6%

Balance sheet

CLYMLLY
Balance sheet
Cash$205M$4.9B
Total debt$1.1M$49.5B
Net debt / EBITDA–1.2
Interest cover–38.9×

Dividends and buybacks

CLYMLLY
Dividends and buybacks
Dividend yield–0.5%
Dividend per share, 12 months–$6.34
Dividend growth a year, past–+15.2%over 5 years
Buyback yield–0.3%
Shareholder yield–0.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CLYM or LLY

Didn't find what you were looking for?

Ask us
Which is bigger, Climb Bio or Eli Lilly and Company?

By market value, Eli Lilly and Company ($1.27T) is about 1,727.9 times Climb Bio ($735M), at today's prices.

How did CLYM and LLY stock do over the last 5 years?

Since November 19, 2021, CLYM's price moved -48.5% and LLY's +416.7%. With dividends: CLYM -48.5% (-12.4% a year), LLY +439.5% (+40.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, CLYM or LLY?

The dividend yield at today's price is none for Climb Bio and 0.47% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.

Which is the better investment, Climb Bio or Eli Lilly and Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.